16 results about "CD1D" patented technology

The invention discloses a preparation method and application of a dual-targeting carrier-free delivery system for enhancing anti-tumor immunity of NKT cells, Lys-alpha-GalCer is used as a raw material, and two molecules of LGC are connected through a disulfide bond to synthesize an amphiphilic LGC-SS-LGC micromolecule prodrug; the LGC-SS-LGC micromolecule prodrug is prepared into vesicles internally loaded with an NKT cell antigen presenting molecule CD1d and externally modified with polysarcosine through electrostatic adsorption through a film dispersion-probe ultrasonic method, finally a CD1d / LGC-SS-LGC / PSar dual-targeting carrier-free delivery system is formed, and the dual-targeting carrier-free delivery system can be used for liver cancer treatment after intravenous administration. In addition, the compound can be used for preparing a preparation for enhancing NKT cell Th1 type immune response. The dual-targeting carrier-free delivery system prepared by the invention can directly or indirectly enhance the anti-tumor immune effect of the NKT cells, and has a dual-synergistic effect.

The invention discloses a preparation method of a silicon dioxide nano vaccine for mediating constant natural killer T (iNKT) cells and application of the silicon dioxide nano vaccine in the field of tumor immunotherapy. The iNKT cell is a special T cell subset which can be activated by a glycolipid antigen presented by CD1d, and can directly kill tumor cells and activate other immune cells. Clinically, the classical agonist alpha GC of the iNKT cell can lead to function depletion of the iNKT cell after multiple intravenous administration, and finally evolves into an inactive state. Although the CD1d / alpha GC protein complex relieves the iNKT cell anenergetic state to a certain extent, the CD1d / alpha GC protein complex is easily degraded and cleared in a complex physiological environment, and the treatment effect is weakened. The characteristics of large aperture and high specific surface area of dendritic mesoporous silica are utilized, CD1d / alpha GC is loaded into a pore channel of a mesoporous nano-material, and the design can protect protein drugs from being degraded in blood circulation, so that a nano-vaccine capable of effectively mediating iNKT cells and successfully relieving the inability of the iNKT cells is constructed; and the effectiveness of the compound in tumor treatment is verified. The patent is supported by the national natural science fund (82001958).

The present invention provides a liposome preparation containing a population of liposomes containing a CD1d ligand compound, wherein the average particle size of the population of liposomes is 90 to 110 nm and the polydispersity index of particle size distribution is 0.2 or less. and the polydispersity index of the particle size distribution is 0.2 or less. The present invention also provides the use of the liposome preparation in the prevention or treatment of graft-versus-host disease and organ transplant rejection.

This invention provides novel compositions and methods for effectively stimulating antiviral immunity. [Solution] A composition comprising (a) a vector comprising a plasmid encoding at least one viral antigen; and (b) a vector comprising a CD1d recognition antigen; and (c) at least one pharmaceutically acceptable carrier, wherein at least one of vectors (a) and (b) is an intact bacterial minicell or a dead bacterial cell.

The present disclosure is directed to compositions comprising fusion proteins of CD1d and anti-GD2 antibody that may be used as GD2-specific Bi-specific invariant natural killer T cell engagers (BiNTEs). Further provided herein are methods of using the fusion proteins or BiNTEs for the treatment of cancer.

The present invention relates to an iNKT-TCR molecule, TCR-T cell, preparation and application targeting a lipid antigen and CD1d complex, and belongs to the field of genetic engineering and immunotechnology. The present invention utilizes specific iNKT amplification technology to amplify and sort iNKT cells, and obtains iNKT cell-enriched TCRs by sequencing analysis. In this study, iNKT cells were amplified by iNKT cell-specific activators, high-purity iNKT cells were obtained by magnetic bead sorting, and iNKT cell-enriched TCRs were accurately screened out based on sequencing analysis to ensure their accuracy and specificity. The NKT38 of the present invention has a higher killing effect on tumor cells that express CD1d and present endogenous lipid antigens, and has strong specificity: in vitro experiments show that iNKT-TCR-transfected NKT38 cells have a stronger killing effect on tumor cell lines that express CD1d and present endogenous lipid antigens, suggesting that it has a specific killing effect on tumors.

The invention belongs to the technical field of chemistry and medicine, and relates to a natural killer T cell agonist which contains a sulfonamide group or a part of the sulfonamide group and has immunoregulatory activity and application of the natural killer T cell agonist. The agonist is a compound with a structure as shown in a formula (1) or a pharmaceutically acceptable salt thereof. According to the invention, a sulfonamide group is introduced to an acyl chain of alpha GalCer, and the binding force between glycolipid molecules and CD1d is enhanced by forming an additional hydrogen bond. By adopting the design concept, the NKT cell agonist with better immunomodulatory activity is obtained, the synthesis method of the series of compounds is simple and efficient, and the screened novel alpha GalCer analogue has obviously improved immunostimulatory activity compared with the original alpha GalCer, can induce immunoreactions with different biases, and has good immunomodulatory activity. Potential candidate drugs are provided for immunotherapy and immune modulation. # imgabs0 #

Embodiments of the disclosure include methods and compositions for immunotherapy that comprise allogeneic cells that are able to be universally tolerated in host individuals. In specific embodiments the cells have reduced expression of endogenous beta2-microglobulin (B2M) and / or MHC class II-associated invariant chain (Ii), and in particular cases the cells are NKT cells that lack the ability to damage host tissues, have much reduced recognition by host immune cells, and surprisingly avoid destruction by host NK cells. In some embodiments, B2M- and / or Ii-targeting molecules are engineered to be expressed in combination (including within a single construct) with recombinantly engineered receptors, for example, for a one-hit generation of universally tolerated off-the-shelf immunotherapy.

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, α-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.

It can remain in the bloodstream for a long period, allowing for the maintenance of high blood concentrations of the active ingredient over extended periods. To provide a liposome formulation containing a CD1d ligand compound that can perform the necessary functions. [Solution] The present invention provides a liposome formulation comprising a group of liposomes containing a CD1d ligand compound, wherein the average particle size of the group of liposomes is 90 to 110 nm, and the polydispersity of the particle size distribution is 0.2 or less. The present invention also provides a method for producing the formulation.

The invention belongs to the technical field of chemistry and medicine, and relates to a natural killer T cell agonist containing a bifurcated or macrocyclic acyl chain structure and having immunoregulatory activity and an application of the natural killer T cell agonist. The agonist is a compound with a structure as shown in a formula (1) or a pharmaceutically acceptable salt thereof. According to the invention, a branched chain or a macrocyclic structure is introduced to an acyl chain of alpha GalCer, so that the binding force between glycolipid molecules and CD1d is enhanced. By adopting the design concept, the NKT cell agonist with better immunomodulatory activity is obtained, the synthesis method of the series of compounds is simple and efficient, and the screened novel alpha GalCer analogue has obviously improved immunostimulatory activity compared with the original alpha GalCer, can induce immunoreactions with different biases, and has good immunomodulatory activity. Potential candidate drugs are provided for immunotherapy and immune modulation.

Compositions and methods for treating diseases such as cancer or viral or bacterial infections are described. More specifically, provided compositions comprise an encapsulated CD1d restricted constant natural killer T cell antigen, a bacterial alpha-galactosylceramide.

The invention provides a nano vaccine targeting iNKT cells, a preparation method of the nano vaccine and application of the nano vaccine in preparation of anti-tumor preparations, and belongs to the technical field of biological medicines. A recombinant protein expression technology is adopted, cysteine is introduced to the C end of CD1d protein, sulfydryl of the cysteine is coupled with maleimide groups on the surfaces of ferroferric oxide nanoparticles, the CD1d protein is directionally coupled to the surfaces of the nanoparticles, then alpha GalCer lipid antigens are loaded, and the nano vaccine capable of directly activating iNKT cells is constructed. The nano vaccine for targeting the iNKT cells simulates dendritic cells in vivo to play an antigen presentation role, further specifically activates the iNKT cells, induces the iNKT cells to proliferate and release cytokines, shows a good immune activation effect in cell and animal experiments, can effectively relieve alphaGalCer-induced iNKT cell inability, and has a good immune activation effect. And an excellent anti-tumor effect is shown in various tumor models.

The present invention discloses a surface molecule that inhibits hepatocyte apoptosis and its application. The present invention experimentally proves for the first time that hepatocyte CD1d (cluster of differentiation 1d) has a highly effective anti-apoptotic liver protection effect, and technically uses adeno-associated virus to specifically overexpress mouse hepatocyte CD1d, or activates CD1d by injecting agonistic monoclonal antibodies into the mouse tail vein, and shows a good anti-apoptotic liver protection effect on hepatocytes in both the non-alcoholic fatty liver hepatitis model and the apoptotic acute liver damage model. The present invention can specifically enhance the anti-apoptosis and anti-damage ability of hepatocytes in advance or actively, and can be used not only for the treatment of acute and chronic liver diseases, but also for the prevention of liver damage. The mechanism of action is specific, so theoretically the toxic and side effects may also be relatively small.

The invention belongs to the technical field of biological medicines, and discloses an immune checkpoint blocking therapy for targeted NKT cells. The platform comprises a hollow mesoporous MnO2 nano catalytic core, a glutamine metabolism regulator PRCG loading layer and surface CD1d-alpha-GalCer compound modification, and through high active oxygen in-situ removal, pH / H2O2 responsive drug release and NKT cell specific targeting, the metabolic activity and the anti-tumor function of the platform are synergistically recovered. The core bottleneck problem of metabolic dysfunction caused by high active oxygen level of NKT cells in a tumor microenvironment is successfully solved by constructing a multifunctional nano-platform integrating targeted recognition, in-situ catalysis and metabolic reprogramming, the oxidative stress in the cells is remarkably reduced, ATP generation and IFN-gamma secretion are improved, and the tumor microenvironment is improved. The tumor suppression effect and the immune memory are enhanced when the polypeptide is combined with a PD-1 antibody, and the polypeptide has good biological safety.

The present disclosure provides a composition having NKT cell activation ability that contains cells incubated with a CD1d ligand prior to CD1d introduction. The present disclosure also provides a composition comprising cells, wherein the cells are human-derived cells and express a complex of CD1d and CD1d ligand on the cell surface and in the cell, respectively, and the amount of the complex in the cells is significantly greater than the amount of the complex on the cell surface. The present disclosure further provides a composition capable of further expressing an antigen and further inducing antigen-specific immunity.